24 completed, 3 terminated, 1 withdrawn. 10 Phase 3, 9 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Withdrawn 1 |
| Phase 4 | 9 | Completed 7, Terminated 2 |
| Not applicable | 1 | Completed 1 |
Follow tiotropium-olodaterol: new trials by email Literature Review of tiotropium-olodaterol trials Research Report on tiotropium-olodaterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ANTES B+ Clinical Trial Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Brimica, Duaklir - Chronic Obstructive Pulmonary Disease | Phase 4 | Terminated | Fundacio Privada Mon Clinic Barcelona | 48 | 2024-02-29 | 2025-08-14 |
| Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data Tiotropium+Olodaterol, Spiolto Respimat, Long-acting muscarinic antagonists (LAMAs) - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 19467 | 2022-09-30 | 2024-12-04 | |
| Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE] tiotropium/olodaterol - Chronic Obstructive Pulmonary Disease | Not applicable | Completed | Yonsei University | 44 | 2021-08-23 | 2026-04-07 |
| Early Intervention Efficacy in COPD Tiotropium/Olodaterol, Tiotropium - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 6788 | 2020-03-27 | 2022-06-14 | |
| Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects Olodaterol-Tiotropium - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Fraunhofer-Institute of Toxicology and Experimental Medicine | 32 | 2020-01-28 | 2023-04-26 |
| A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale Tiotropium + olodaterol, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | Boehringer Ingelheim | 213 | 2020-01-08 | 2021-11-18 |
| A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment Tiotropium + Olodaterol, Other LABA/LAMA, LAMA - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 1617 | 2019-12-29 | 2022-06-14 | |
| Re-usable Respimat® Soft MistTM Inhaler Study Respimat - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 262 | 2019-09-30 | 2021-03-03 | |
| Impact of Tiotropium Add-on Therapy in Patients With Asthma Tiotropium Respimat®, Inhaled Corticosteroid/Long-acting beta-agonist - Asthma | Completed | Boehringer Ingelheim | 7857 | 2019-03-15 | 2020-11-03 | |
| Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease Bronchodilator Agents - Pulmonary Disease, Chronic Obstructive | Phase 4 | Terminated | Università degli Studi di Ferrara | 843 | 2018-11-11 | 2022-12-28 |
| Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE] Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy) - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | Boehringer Ingelheim | 714 | 2017-09-20 | 2022-06-14 |
| INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol Tiotropium & olodaterol, fluticasone furoate & vilanterol - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | University of Dundee | 80 | 2017-06-01 | 2020-07-20 |
| The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease Stiolto Respimat, Placebo Respimat - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 14 | 2017-03-01 | 2020-08-06 |
| Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD Tiotropium + Olodaterol, PLACEBO - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Queen's University | 25 | 2017-01-01 | 2019-02-05 |
| Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO) Spiolto Respimat - Pulmonary Disease, Chronic Obstructive | Terminated | Boehringer Ingelheim | 132 | 2016-08-26 | 2019-04-16 | |
| Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease Spiolto - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 1335 | 2016-08-23 | 2019-12-06 | |
| Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg, olodaterol 2.5 mcg - Asthma | Phase 4 | Completed | University of Dundee | 17 | 2016-07-11 | 2019-06-21 |
| Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice Spiolto Respimat - Pulmonary Disease, Chronic Obstructive | Completed | Boehringer Ingelheim | 1737 | 2016-01-13 | 2018-10-15 | |
| Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. NVA237, Tiotropium Respimat® - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2014-04-01 | 2016-08-22 | |
| To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways placebo to tiotropium + olodaterol, tiotropium+olodaterol, tiotropium +olodaterol - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | Boehringer Ingelheim | 304 | 2014-03-01 | 2017-01-06 |
Showing 20 of 28. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (25) · Asthma (3)
Boehringer Ingelheim (19) · University of Dundee (2) · Fraunhofer-Institute of Toxicology and Experimental Medicine (1) · Fundacio Privada Mon Clinic Barcelona (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Novartis Pharmaceuticals (1) · Queen's University (1) · Università degli Studi di Ferrara (1) · Yonsei University (1)
Germany (11) · United States (11) · Canada (8) · Belgium (6) · Japan (6) · Denmark (5) · Netherlands (5) · United Kingdom (5) · Argentina (4) · Austria (4) · Hungary (4) · Italy (4) · Australia (3) · China (3) · Finland (3)
Brian Lipworth, MD, Mb Chb (1) · Harry Rossiter, PhD (1) · J Alberto Neder, Prof (1) · James Chalmers, MBChB, MRCP (1) · Ji Ye Jung (1) · Richard Casaburi, PhD, MD (1) · Sunny Jabbal, Mb Chb (1)
PMID 25573406, PMID 26112656, PMID 27993292, PMID 28424359, PMID 29355547, PMID 30261995, PMID 32462607, PMID 32671684, PMID 32776202, PMID 32848379, PMID 32848380, PMID 32943047, PMID 33175291, PMID 25894430, PMID 25956072, PMID 27044576, PMID 27075841, PMID 29439648, PMID 31319851, PMID 32857327, PMID 33180376, PMID 33548471, PMID 34394782, PMID 35323052, PMID 35948844, PMID 36472162
2009 (2), 2014 (1), 2016 (1), 2019 (1), 2023 (1)